United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
528.47
-1.06 (-0.20%)
Jul 24, 2026, 4:00 PM EDT - Market closed
United Therapeutics Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 3,170 | 3,183 | 2,877 | 2,328 | 1,936 | 1,686 |
Revenue Growth | 5.87% | 10.61% | 23.63% | 20.20% | 14.88% | 13.63% |
Gross Profit Gross Profit Growth | 2,745 | 2,798 | 2,568 | 2,070 | 1,785 | 1,563 |
Operating Income Operating Income Growth | 1,436 | 1,493 | 1,377 | 1,185 | 979.7 | 555.9 |
Net Income Net Income Growth | 1,287 | 1,335 | 1,195 | 984.8 | 727.3 | 475.8 |
Earnings Per Share EPS Growth | 27.09 | 27.86 | 24.64 | 19.81 | 15.00 | 10.06 |
EPS Growth | 8.10% | 13.07% | 24.38% | 32.07% | 49.10% | -12.83% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Tyvaso Tyvaso Growth | 1,869 | 1,878 | 1,620 | 1,234 | 873 | 607.5 |
Remodulin Remodulin Growth | 515.2 | 526.8 | 538.1 | 494.8 | 500.2 | 513.7 |
Orenitram Orenitram Growth | 511.8 | 496.9 | 434.3 | 359.4 | 325.1 | 306.1 |
Unituxin Unituxin Growth | 222.2 | 226.8 | 238.7 | 198.9 | 182.9 | 202.3 |
Adcirca Adcirca Growth | 26.9 | 30 | 23.8 | 28.9 | 41.3 | 55.9 |
Revenue (Total) Revenue (Total) Growth | 3,170 | 3,183 | 2,877 | 2,328 | 1,936 | 1,686 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 2,154 | 2,920 | 3,267 | 2,994 | 2,839 | 1,931 |
Total Debt Total Debt Growth | 0 | 0 | 300 | 700 | 800 | 800 |
Net Cash (Debt) Net Cash Growth | 2,154 | 2,920 | 2,967 | 2,294 | 2,039 | 1,131 |
Net Cash Growth | -31.00% | -1.57% | 29.33% | 12.53% | 80.30% | 9.25% |
Net Cash Per Share Net Cash Per Share Growth | 45.32 | 60.97 | 61.18 | 46.16 | 42.04 | 23.90 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 1,563 | 1,561 | 1,327 | 978 | 802.5 | 598.2 |
Capital Expenditures CapEx Growth | -546.4 | -520.5 | -246.5 | -230.4 | -138.8 | -120.8 |
Free Cash Flow Free Cash Flow Growth | 1,017 | 1,041 | 1,081 | 747.6 | 663.7 | 477.4 |
Free Cash Flow Growth | -9.90% | -3.69% | 44.54% | 12.64% | 39.02% | -31.45% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 86.58% | 87.92% | 89.24% | 88.94% | 92.17% | 92.73% |
Operating Margin | 45.29% | 46.89% | 47.86% | 50.91% | 50.60% | 32.98% |
Pretax Margin | 50.75% | 53.85% | 53.49% | 54.75% | 49.09% | 35.24% |
Profit Margin | 40.61% | 41.94% | 41.53% | 42.31% | 37.56% | 28.23% |
FCF Margin | 32.08% | 32.70% | 37.55% | 32.12% | 34.28% | 28.32% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.53 | 17.49 | 14.32 | 11.10 | 18.54 | 21.48 |
Forward PE | 18.72 | 17.14 | 12.17 | 9.93 | 13.57 | 13.45 |
P/FCF Ratio | 22.06 | 20.43 | 14.64 | 13.84 | 19.29 | 20.40 |
PS Ratio | 7.08 | 6.68 | 5.50 | 4.44 | 6.61 | 5.78 |